Press Releases

Press Releases

July 11, 2018

CAMBRIDGE, Mass. and CARLSBAD, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), announced today that TEGSEDI TM (inotersen) has received marketing authorization approval

July 5, 2018
-TEGSEDI treatment demonstrated substantial improvement in measures of neuropathy progression and quality of life- -Akcea prepared for launch following approval- CARLSBAD, Calif. , and CAMBRIDGE, Mass. , July 5, 2018 /PRNewswire/ --  Ionis Pharmaceuticals, Inc.
June 13, 2018

Results published in Expert Review of Cardiovascular Therapy CAMBRIDGE, Mass. , June 13, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat people with serious and rare diseases,

June 12, 2018

hATTR Compass to provide no-cost, confidential genetic testing and genetic counseling services, potentially enabling faster diagnosis CAMBRIDGE, Mass. , June 12, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.

June 5, 2018

CAMBRIDGE, Mass. , June 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced the appointment of Richard (Rich) A. Moscicki , M.D., to the Company’s Board of Directors. “Rich is an experienced, well-respected industry

June 1, 2018

CAMBRIDGE, Mass. and CARLSBAD, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the

May 29, 2018

CAMBRIDGE, Mass. , May 29, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , today announced that management will present a company overview at the Jefferies Global Healthcare Conference at 9:30 a.m.

May 10, 2018

Advisory Committee members vote 12-8 to support approval CAMBRIDGE, Mass. and CARLSBAD, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the U.S.

May 3, 2018

TTR licensing transaction positions Akcea for two rare disease drug launches in 2018 FDA extended TEGSEDI TM (inotersen) PDUFA date to October 6, 2018 $445 million in pro forma cash to fund the company through key milestones in 2019 Conference Call Webcast Thursday, May 3 , 4:30 p.m.

May 2, 2018

Program currently available in the U.S. and select countries in Europe; initiating additional countries throughout 2018 CAMBRIDGE, Mass. , May 02, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA) today announced it has expanded its global early access program (EAP) to the United